Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation

This publication has 21 references indexed in Scilit:

• The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth
  Emerging Therapeutic Targets, 2003
• Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
  Genes & Development, 2003
• Addiction to Oncogenes--the Achilles Heal of Cancer
  Science, 2002
• Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
  Science, 2002
• Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression
  Cell, 2002
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology
  The FASEB Journal, 2002
• Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
  Genes & Development, 2001
• c-Myc in breast cancer.
  Endocrine-Related Cancer, 2000
• Reversible Activation of c-Myc in Skin
  Molecular Cell, 1999